http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-1506755-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7f6e33603375c486b0ab3505830af9e8 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02P20-55 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-93 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D317-72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C405-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D317-72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-93 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C405-00 |
| filingDate | 1975-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1978-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-1506755-A |
| titleOfInvention | Pharmaceutically useful prostenoic acid derivatives |
| abstract | 1506755 Prostaglandins SANKYO CO Ltd 21 May 1975 21845/75 Heading C2C The invention comprises prostaglandins of the Formula I wherein R<SP>2</SP> and R<SP>3</SP> each are C 1-4 alkyl and R<SP>4</SP> is H or C 1-4 alkyl and pharmaceutically acceptable salts thereof where R<SP>4</SP> is H, and their preparation. The prostaglandins are obtained by removing the carbonyl protecting groups from compounds of the Formula II which are made by reducing the corresponding 15-oxo compounds, resulting from the reaction between compounds of the formula with the appropriate cyclopentanecarboxaldehydes. Methyl 7-(5,5 - ethylenedioxy - 2# - formyl - 3α- methyl - 1α - cyclopentyl)heptanoate is prepared by oxidizing methyl 7 - (5,5 - ethylenedioxy - 2#- hydroxymethyl - 3α - methyl - 1α - cyclopentyl) heptanoate, resulting from the reaction between ethylene glycol and methyl 7 - (2# - hydroxymethyl - 3α - methyl - 5 - oxo - 1α - cyclopentyl) heptanoate, which is obtained by treating 2# - hydroxymethyl - 1α - (6 - methoxycarbonylhexyl) - 3α - methyl - 5 - oxo - 1# - cyclopentanecarboxylic acid γ-lactone with bases, the lactone being obtained by reacting ethyl 7-iodoheptanoate with 2# - hydroxymethyl - 3α - methyl - 5- oxo - 1# - cyclopentanecarboxylic acid γ-lactone, resulting from reacting potassium t-butoxide with 3# - ethoxycarbonyloxymethyl - 4α - methylcyclopentan - 1 - one, which is prepared by hydrolysing 3# - ethoxycarbonyloxymethyl - 4α- methylcyclopentan - 1 - one ethylene acetal, obtained by reacting ethyl chloroformate with 3# - hydroxymethyl - 4α - methylcyclopentan- 1 - one ethylene acetal, the latter being obtained by reducing ethyl 8α-methyl-1,4-dioxaspiro[4,4]nonane - 7# - carboxylate, which is prepared by reacting sodium ethoxide with ethyl 8α - methyl - 1,4 - dioxospiro[4,4]nonone - 7α- carboxylate, obtained by reacting ethylene glycol with ethyl 2α - methyl - 4 - oxo - 1α - cyolopentanecarboxylate, which is prepared by treating 2#- methoxycarbonyl - 3α - methyl - 4α - ethoxycarbonylcyclopentanone with sodium iodide and glacial acetic acid. Pharmaceutical compositions, suitable for oral and parenteral administration, contain the above prostaglandins or salts thereof together with pharmaceutical carriers or diluents. The compounds possess anti-ulcerogenic activity. |
| priorityDate | 1975-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 39.